Skip to main content
1006-2023, 1005-2016, 1005-2015
class com.aha.ucm.component.cis.TagListPageData=[,docNativeURL=null,docName=UCM_497322,docStatus=RELEASED,dOutDate=null,docSSFileName=UCM_497322_AHA-Principles-on-the-Accessibility-and-Affordability-of-Drugs-and-Biologics.jsp,docTitle=AHA Principles on the Accessibility and Affordability of Drugs and Biologics,xWebsites=professional,dDocAuthor=stacy.ragsdale,xNextReviewDate=09/22/2016 5:42 PM,xTier1=36,xFeaturedItem=No,xElectronicRegistration=No,UserLocale=null,xSubCategory=,dpEvent=null,xComments=Market entry prices of innovator pharmaceutical products, or brand drugs and biologics, are at levels that some assessments consider unaffordable to the healthcare system and prices for some established generic drugs have seen sharp, and rapid increases. These two trends are converging to create a situation that requires serious consideration by all healthcare stakeholders.,NoHttpHeaders=null,UserTimeZone=null,xRegionDefinition=GENERIC_RD_COL_1,xVideoRenditions=,xSnippetItem=,xNotes=,UserDateFormat=null,encodeDocUrl=null,isDocProfileDone=null,xKeywords=biologics; cost containment; drugs; generic drugs; out-of-pocket costs,xTier2=,refreshSubMonikers=null,xEditorStepReassignedUsers=null,xLinkTextToDisplay=,dDocAccount=WCM/SOP/SMD,xEndDateTime=null,xClbraAliasList=null,ClientEncoding=null,xCpdIsLocked=0,xUsageRightsDate=null,xModifyDate=11/09/2017 2:54 PM,xTier3=,xEventDate=null,dSubscriptionType=null,xCopyright=No,xPackagedConversions=,dSubscriptionAlias=null,xStorageRule=,dpName=null,xDepartment=Science Operations,dStatus=RELEASED,dPublishType=,xCopyrightDetails=,xSubType=64,isDocProfileUsed=null,xWebsiteObjectType=Data File,xWebFlag=,xSeeAlsoLinks=,xClbraUserList=null,xPartitionId=,xCpdIsTemplateEnabled=0,xLinkWebAddress=,xDontShowInListsForWebsites=,xStartDateTime=null,dInDate=11/09/2017 2:53 PM,xWebsiteSection=professional:1463,dDocName=UCM_497322,dpAction=null,dRevLabel=2,dSecurityGroup=AHAMAH-Public,xCategory=,refreshMonikers=null,xDamConversionType=,dDocFormats=null,xAssociatedImage=,dDocType=SingleColumn,xBusinessOwner=Business Owner,xUploadDate=null,xDiscussionCount=0,xMainFlowEntryCriteria=True,xItemInformation=,xUsageRights=,xDiscussionType=N/A,xRecipeTaxonomy=,dSubscriptionID=null,dOriginalName=UCM_497322.xml,xProfileTrigger=SingleColumn,dLocation=,dRevisionID=2,dPublishState=,dReleaseState=Y,xTrashDeleter=null,dMessage=,dWebExtension=xml,dExtension=xml,dProcessingState=Y,xTrashDeleteName=null,dIsCheckedOut=0,xForceFolderSecurity=null,dRevClassID=497322,dIsPrimary=1,dFileSize=15593,dIndexerState=,dFlag1=,xviaAddNewContentService=,dIsWebFormat=0,xCollectionID=null,dRevRank=0,xReadOnly=null,dCheckoutUser=,dFormat=Application/xml,dWorkflowState=,dDocID=1795850,dRendition2=,dRendition1=,xInhibitUpdate=null,dReleaseDate=11/09/2017 2:56 PM,xTrashDeleteLoc=null,dCreateDate=11/09/2017 2:54 PM,xHidden=null,labelTier1=ScienceNews,labelTier2=,labelTier3=,labelTier4=,mobileNavURL=DEFAULT2_VALUE_FROM_getDataForAdvanceSearch,xContactPhoneNumber=,xContactEmailAddress=,xContactName=,xATGRolesDisciplines=,xPublishDate=11/09/2017 10:00 AM,xRobotParameter=,xCommunities=1006-2023, 1005-2016, 1005-2015,xMembershipLevel=,rsCalories=null,rsSodium=null,rsRecipeTaxonomy=null,rsServings=null,rsTotalTime=null,rsTotalFat=null,rsTotalCarbs=null,rsFeaturedImage=null,xDisplayComments=

American Heart Association Principles on the Accessibility and Affordability of Drugs and Biologics

  • Market entry prices of innovator pharmaceutical products, or brand drugs and biologics, are at levels some consider unaffordable and prices for some generic drugs have seen sharp, rapid increases. These troublesome trends warrant serious consideration by all healthcare stakeholders.
  • The American Heart Association consistently has advocated for equity and affordability and will continue to pursue equitable access for all.
  • To support patients in addressing rising drug costs and curtail the associated adverse health impacts, the AHA developed a set of principles to guide its advocacy and help frame the ongoing debate.

Read the full article in Circulation